Gilead Signs an Agreement with Nurix to Develop and Commercialize Protein Degradation Therapies for Cancer and Other Disease

Shots:

• Nurix to receive $45M upfront, up to $2.3B as milestones and royalties on sales, and will identify novel targets, utilizing its discovery platform & E3 ligases inducing degradation of targets. Nurix retains an option to co-develop and co-detail up to 2 programs with equal profit & loss sharing with split cost in the US, receives royalties on sales (Ex-US) & reduced milestones for opted programs
• Gilead to get an option to license drug candidates up to 5 targets developed by Nurix and get rights to develop & commercialize targeted protein degradation drugs for patients with cancer and other challenging diseases
• Nurix’s technology platform focuses on the manipulation of the ubiquitin system and its component E3 ligases, responsible for controlling protein levels in human cells

Click here to read full press release/ article | Ref: Gilead | Image: Touch Creative